ID: ALA389978

Max Phase: Preclinical

Molecular Formula: C23H28N6O3

Molecular Weight: 436.52

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1cc2nc(N3CCN(C(=O)c4ccc[nH]4)[C@H]4CCCC[C@H]43)nc(N)c2cc1OC

Standard InChI:  InChI=1S/C23H28N6O3/c1-31-19-12-14-16(13-20(19)32-2)26-23(27-21(14)24)29-11-10-28(17-7-3-4-8-18(17)29)22(30)15-6-5-9-25-15/h5-6,9,12-13,17-18,25H,3-4,7-8,10-11H2,1-2H3,(H2,24,26,27)/t17-,18+/m0/s1

Standard InChI Key:  YJXHORZMAAZIFY-ZWKOTPCHSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 436.52

Molecular Weight (Monoisotopic): 436.2223

AlogP: 2.83

#Rotatable Bonds: 4

Polar Surface Area: 109.60

Molecular Species: NEUTRAL

HBA: 7

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 7.21

CX LogP: 3.00

CX LogD: 2.79

Aromatic Rings: 3

Heavy Atoms: 32

QED Weighted: 0.65

Np Likeness Score: -0.66

References

1. Sagratini G, Angeli P, Buccioni M, Gulini U, Marucci G, Melchiorre C, Leonardi A, Poggesi E, Giardinà D..  (2007)  Synthesis and alpha(1)-adrenoceptor antagonist activity of derivatives and isosters of the furan portion of (+)-cyclazosin.,  15  (6): [PMID:17276073] [10.1016/j.bmc.2007.01.028]

Source

Source(1):

• Scientific Literature